

Codexis Pipeline Snapshot – June 30th 2019

Codexis Pipeline Snapshot – June 30th 2019

Pipeline Project Category	Pre-Commercial		Commercial	Pipeline Total	<i>vs. prior pipeline</i>
	Codexis Driven		Sustaining Revenues		
	<i>Codexis Self-funded</i>	<i>Customer Partnered</i>	<i>Product Sales and/or Licensing</i>	06/30/2019	6/30/18
Performance Enzymes Improving Pharma Manufacturing:					
<i>Clinical Phases II or III</i>		15	n.a.	15	+1
<i>Patented On-the-Market Drugs</i>		1	3	4	+1
<i>Generic On-the-Market Drugs</i>	1	4	6	11	+2
Discovery & Development of Novel Biotherapeutics	7	3		10	+1
Improving Products & Processes ex-Pharmaceuticals:					
<i>Food Ingredients</i>	1	3	2	6	+2
<i>Molecular Biology & Molecular Diagnostic Enzymes</i>	3	2		5	+2
<i>Industrial Enzymes</i>		1		1	-
Pipeline Total as of June 30, 2019	12	29	11	52	+9

Guide to Codexis Pipeline Snapshot

Row Headers

- Independent categories in which Codexis is creating protein innovations that can liberate value-in-use
- Excludes biocatalysts for small molecule pharmaceuticals prior to and through Phase 1 development, as they are too numerous, unclear regards to stage of development and collectively of minimal revenue impact

Column Headers


- **ALL Projects are Codexis Driven** – projects where protein innovations have been or are being developed by Codexis teams
- **Pre-Commercial** are projects that have yet to be fully commercially launched by Codexis and/or our customers
- **Commercial** projects or products that have been fully commercialized by both Codexis and our customers and are sources of sustained revenues for Codexis

For a Project to register in our Pipeline

- It must have generated > \$100,000 in revenue and/or incurred > \$100,000 in costs over the prior 2 years

Strong and Growing Opportunity Pipeline

Total Pipeline Growth 2016-2019



Pipeline Distribution and Growth by Segment 2016-2019

